On January 3, 2022 Ryvu Therapeutics (WSE: RVU), a clinical stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, reported that it will participate in the following upcoming virtual investor conferences (Press release, Ryvu Therapeutics, JAN 3, 2022, https://www.prnewswire.com/news-releases/ryvu-therapeutics-to-participate-in-the-lifesci-partners-11th-annual-corporate-access-event-and-hc-wainwright-bioconnect-conference-301452631.html [SID1234597996]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

11th Annual LifeSci Partners Corporate Access Event, taking place January 5-7, 2022; Ryvu Therapeutics will host 1×1 investor meetings during the conference.
Registration: LifeSci Partners Corporate Access Event 2022

H.C. Wainwright Bioconnect Virtual Conference, taking place January 10-13, 2022;
Ryvu’s pre-recorded corporate presentation will be available on-demand on the event platform, starting January 10, 7:00 AM (ET). Ryvu’s Management Board will also host investor meetings during the conference.